Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Transcutaneous lisuride therapy of Parkinson's disease

Trial Profile

Transcutaneous lisuride therapy of Parkinson's disease

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Lisuride (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2008 Axxonis submitted MAA to EMEA for transdermal lisuride as add-on therapy for Parkinson's Disease and Restless Legs Syndrome.
    • 25 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top